Behnes, Michael
Lahu, Shqipdona http://orcid.org/0000-0003-3085-7403
Ndrepepa, Gjin
Menichelli, Maurizio
Mayer, Katharina
Wöhrle, Jochen
Bernlochner, Isabell
Gewalt, Senta
Witzenbichler, Bernhard
Hochholzer, Willibald
Sibbing, Dirk
Cassese, Salvatore
Angiolillo, Dominick J.
Hemetsberger, Rayyan
Valina, Christian
Müller, Arne
Kufner, Sebastian
Hamm, Christian W.
Xhepa, Erion
Hapfelmeier, Alexander
Sager, Hendrik B.
Joner, Michael
Fusaro, Massimiliano
Richardt, Gert
Laugwitz, Karl-Ludwig
Neumann, Franz-Josef
Schunkert, Heribert
Schüpke, Stefanie
Kastrati, Adnan
Akin, Ibrahim
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
https://doi.org/10.1007/s00392-022-02040-z
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention
https://doi.org/10.1161/circinterventions.121.010565
Early clinical outcomes as a function of use of newer oral P2Y<sub>12</sub>inhibitors versus clopidogrel in the EUROMAX trial
https://doi.org/10.1136/openhrt-2017-000677
Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
https://doi.org/10.1161/atvbaha.122.318614
Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
https://doi.org/10.1055/a-1988-5047
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk
https://doi.org/10.1161/circinterventions.122.012204
Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
https://doi.org/10.1161/circulationaha.120.050244
Funding for this research was provided by:
German Center for Cardiovascular Research (DZHK); Deutsches Herzzentrum München (FKZ 81X1600501)
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 31 March 2022
Accepted: 9 May 2022
First Online: 5 July 2022
Declarations
:
: The authors report the following conflicts of interest: Dr. Bernlochner has received lecture fees from Sysmex Europe GmbH; Dr. Hochholzer reports personal fees from Bayer Vital, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Novartis, AstraZeneca, The Medicines Company; Dr. Sibbing has received personal fees from Daichi Sankyo, Sanofi and Astra Zeneca, Bayer, Pfizer and Servier; Dr. Angiolillo reports grants and personal fees from Amgen, Aralez, Astra Zeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merc, Sanofi, CeloNova, personal fees from Haemonetics, PhaseBio, PLx Pharma, Pfizer, The Medicines company, St Jude Medical, grants from CSL Behring, Eisai, Gilead, Idorsia Pharmaceuticals Ltd, Matsutani Chemical Industry Co., Novartis, Osprey Medical, Renal Guard Solutions, Scott R. MacKenzie Foundation; Dr. Hemetsberger received speaker’s honoraria from Boston Scientific; Dr. Kufner reports personal fees from Bristol Myers Squibb, Astra-Zeneca, and Translumina; Dr. Sager reports grants from European Research Council, Else-Kröner-Fresenius-Stiftung, Deutsche Herzstiftung, Deutsche Forschungsgemeinschaft; Dr. Neumann has received personal fees from Amgen, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, and Ferrer; has received grants and personal fees from Pfizer, Biotronik, Edwards Lifesciences, Bayer Healthcare, and Boston Scientific; and has received grants from Medtronic and GlaxoSmithKline outside the submitted work; Dr. Schunkert has received personal fees from Merck Sharp & Dohme, Amgen, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi, Synlab; and has received grants and personal fees from AstraZeneca; Dr. Schüpke has received the Else Kröner-Memorial grant from the Else Kröner-Fresenius-Stiftung, financial support from the German Center for Cardiovascular Research (DZHK) and consulting fees from Bayer Vital GmbH and lecture fees from Daiichi Sankyo and Biopas Laboratories; Dr. Akin has received lecture fees from Boston Scientific, Boehringer, Daiichi Sankyo, Gore. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.